Have you tested POSITIVE for COVID-19 ?
You might qualify for MONOCLONAL ANTIBODY THERAPIES
Monoclonal Antibodies (mAbs) are engineered proteins, derived from patients who have recovered from COVID-19. They target and bind to specific spots on the virus, preventing it from entering human cells. (NOTE: Monoclonal antibodies are NOT a substitute for COVID-19 vaccines.)
On Jan. 24, 2022, the FDA pulled its authorization of 2 of the 3 most widely used monoclonal antibodies Regeneron (casirivimab and imdevimab) and Eli Lilly (bamlanivimab and etesevimab - administered together), as these 2 older monoclonals were ineffective against, and unable to bind to Omicron.
Sotrovimab (GlaxoSmithKline) is now recommended as the primary monoclonal antibody treatment for COVID-19, as it remains effective against Omicron - but is in short supply across the country. Evusheld (AstraZeneca) has been shown to prevent severe disease in people with weakened immune systems.
Other available therapies including Paxlovid and Molnupiravir, two pills patients can take at home to reduce the risk of hospitalization from severe COVID-19, and the antiviral drug Remdesivir (Veklury), for which the FDA recently expanded use and approval.
Monoclonal Antibodies (mAbs) can help those with mild to moderate COVID-19 when given within the first 5-10 days of symptoms. Treatments can prevent hospitalizations and / or severe complications.)
Anyone 12+ years (and 88+ lbs) may qualify for treatment if they have a positive COVID test result and are at high risk for developing severe COVID, (either by infusion or injection).
Doctors consider multiple factors in determining what is right for each patient, including:
Benefit / risk for an individual patient, and
Factors such as race or ethnicity that may place an individual patient at higher risk.
The Expanded Use Authorization (EUA) does NOT limit the authorization of treatments to the medical conditions or factors listed below - Physicians are encouraged to use their judgement.
For additional information, see CDC link regarding Certain Underlying Medical Conditions.
HealthData.gov:
COVID-19 Public Therapeutic Locator
Dataset only includes locations for Evusheld (monoclonal antibody), Molnupiravir (antiviral), and Paxlovid (Antiviral). (Requires a prescription)
Are you 65 or older?
(If YES, YOU QUALIFY. Click below)
If 18 - 64 years old AND have…
Older age (for example ≥65 years of age)
Obesity (Adults) or
Being overweight (BMI >25 see calculator) or
Pregnancy or
Diabetes or
Immunosuppressive disease or treatment or
Cardiovascular disease (including congenital heart disease) or hypertension or
Asthma [moderate-to-severe] or
Chronic lung diseases (eg: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis and pulmonary hypertension) or
Sickle Cell Disease or
Neurodevelopmental Disorders (eg: cerebral palsy) or other conditions that confer medical complexity (eg: example, genetic or metabolic syndromes and severe congenital anomalies) or
A medical-related technological dependence (eg: Tracheostomy, Gastrostomy or positive pressure ventilation (not related to COVID-19)
(If YES, click below)
If 12-17 years, you MUST weigh 88lbs (40+kg) AND have one one of…
Obesity (BMI ≥ 85th percentile for age / gender based on CDC growth charts), or
Pregnancy or
Diabetes or
Immunosuppressive disease or treatment or
Cardiovascular disease (including congenital heart disease) or hypertension or
Asthma [moderate-to-severe] or
Chronic lung diseases (eg: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis and pulmonary hypertension) or
Sickle Cell Disease or
Neurodevelopmental Disorders (eg: Cerebral Palsy), or other conditions that confer medical complexity (eg: genetic or metabolic syndromes & severe congenital anomalies) or
A Medical-related technological dependence (eg: Tracheostomy, Gastrostomy or positive pressure ventilation -unrelated to COVID-19)
(If YES, click below)
